The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers

Hereditary Cancer in Clinical Practice

Volumn 13, Issue 1, 2015, Pages

  Cavanagh, Helen ^a   Rogers, Katherine M A ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

BRCA1; BRCA2; Non breast ovarian cancers; Pancreatic cancer; Prostate cancer; Stomach cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GERMLINE MUTATION; HETEROZYGOTE; HUMAN; MALE; ONSET AGE; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; REVIEW; STOMACH CANCER; SURVIVAL RATE;

EID: 84938086836     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/s13053-015-0038-x     Document Type: Review

References (46)

1. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25:5864-74.
2. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95:866-71.
3. Kumar P, Clark ML. Kumar and Clark's Clinical Medicine, 8e: Saunders Ltd., London. 2012.
4. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 2006;34:1416-26.
5. Berger E. New finding may unlock secrets of BRCA mutations. 2010. Available at: http://www.cancer.org/cancer/news/news/finding-may-unlock-secrets-of-brca-mutations. Acessed 30th July 2015.
6. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71.
7. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265:2088-90.
8. NCI. BRCA1 & BRCA2: Cancer Risk & Genetic Testing. 2014. Available at: http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA. Acessed 30th July 2015.
9. NCI. Genetics of Breast and Ovarian Cancer (PDQ®). 2014. Available at: http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page1. Acessed 30th July 2015.
10. CRUK. Breast cancer risk factors. UK: Cancer Research; 2014.
11. Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer. 2010;103:918-24.
12. CRUK. Breast cancer Key Facts. UK: Cancer Research; 2014.
13. Alanee SR, Glogowski EA, Schrader KA, Eastham JA, Offit K. Clinical features and management of BRCA1 and BRCA2-associated prostate cancer. Front Biosci (Elite Ed). 2014;6:15-30.
14. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, Jonasson JG, Olafsdottir EJ, Olafsdottir GH, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99:929-35.
15. Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010;16:2115-21.
16. Edwards SM, Eeles RA. Unravelling the genetics of prostate cancer. Am J Med Genet C Semin Med Genet. 2004;129c:65-73.
17. Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer. 2008;99:371-4.
18. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers, Breast Cancer Linkage Consortium. Lancet. 1994;343:692-5.
19. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94:1358-65.
20. BCLC. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310-6.
21. Thiessen EU. Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer. 1974;34:1102-7.
22. Anderson DE, Badzioch MD. Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst. 1992;84:1114-7.
23. Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ. 1992;305:855-7.
24. Agalliu I, Gern R, Leanza S, Burk RD. Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations. 2009.
25. Agalliu I, Kwon EM, Zadory D, McIntosh L, Thompson J, Stanford JL, et al. Germline Mutations in the BRCA2 Gene and Susceptibility to Hereditary Prostate Cancer. 2007.
26. Bermejo JL, Hemminki K. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. 2004.
27. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 2003;72:1-12.
28. CRUK. Pancreatic cancer statistics. UK: Cancer Research; 2014.
29. Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, et al. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer. 2012;118:493-9.
30. Lucas AL, Frado LE, Hwang C, Kumar S, Khanna LG, Levinson EJ, et al. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer. 2014;120:1960-7.
31. Greer JB, Whitcomb DC. Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut. 2007;56:601-5.
32. Lynch HT, Deters CA, Lynch JF, Brand RE. Familial pancreatic carcinoma in Jews. Fam Cancer. 2004;3:233-40.
33. Naderi A, Couch FJ. BRCA2 and pancreatic cancer. Int J Gastrointest Cancer. 2002;31:99-106.
34. Axilbund JE, Argani P, Kamiyama M, Palmisano E, Raben M, Borges M, et al. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther. 2009;8:131-5.
35. Tulinius H, Olafsdottir GH, Sigvaldason H, Arason A, Barkardottir RB, Egilsson V, et al. The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet. 2002;39:457-62.
36. Kim DH, Crawford B, Ziegler J, Beattie MS. Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. Fam Cancer. 2009;8:153-8.
37. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700-10.
38. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94:1365-72.
39. Jakubowska A, Scott R, Menkiszak J, Gronwald J, Byrski T, Huzarski T, et al. A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer. Eur J Hum Genet. 2003;11:955-8.
40. Jakubowska A, Nej K, Huzarski T, Scott RJ, Lubinski J. BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer. 2002;87:888-91.
41. Schlebusch CM, Dreyer G, Sluiter MD, Yawitch TM, van den Berg HJ, van Rensburg EJ. Cancer prevalence in 129 breast-ovarian cancer families tested for BRCA1 and BRCA2 mutations. S Afr Med J. 2010;100:113-7.
42. Van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, et al. Netherlands Collaborative Group on Hereditary Breast C. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005;42:711-9.
43. Figer A, Irmin L, Geva R, Flex D, Sulkes J, Sulkes A, et al. The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer. 2001;84:478-81.
44. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269-75.
45. Daly PA, Nolan C, Green A, Ormiston W, Cody N, McDevitt T, et al. Predictive testing for BRCA1 and 2 mutations: a male contribution. Ann Oncol. 2003;14:549-53.
46. Hallowell N, Ardern-Jones A, Eeles R, Foster C, Lucassen A, Moynihan C, et al. Men's decision-making about predictive BRCA1/2 testing: the role of family. J Genet Couns. 2005;14:207-17.